Receive a copy of our current research models and services product guide.
Revolutionize Drug Discovery with Inotiv’s Comprehensive Neuroscience Program
Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.
Reduce costs with our complimentary sample for evaluation in your lab.
Search by therapeutic area, research phase, and products and services at inotiv.com.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
October 22-23, 2024 Somerset, NJ Booth #13
October 28-30, 2024 Research Triangle Park, NC Please join us in Research Triangle Park, North Carolina as we continue to grow the impact of the society ...
October 30, 2024 9 am—11 am Mainz, Germany Join our seminar this October at the University of Mainz!
September 16, 2024 WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Comp...
September 6, 2024 Inotiv is pleased to announce that our Talent Acquisition team has been selected as one of ...
August 28, 2024 WEST LAFAYETTE, Ind., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a lead...
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Copyright © 2024 Inotiv. All Rights Reserved.